New to peptides? Start with the foundations ->
The dad-test answer
The semaglutide shortage was officially resolved by the FDA in February 2025, which closed the legal door on large-scale compounding for semaglutide. 503A pharmacies had until April 22, 2025; 503B outsourcing facilities had until May 22, 2025. After those windows, branded Wegovy (or Ozempic for diabetes) is the legitimate path - and quality control is a non-issue with FDA-supervised cGMP manufacturing. If a reader is still on a compounded protocol in 2026, that should trigger a check on the source pharmacy's legal basis.
Who wins for what
| Use case | Who wins, and why |
|---|---|
| regulatory legality in 2026 |
wegovy (branded) FDA closed the shortage list for semaglutide Feb 2025; large-scale compounding outside narrow exceptions is no longer permitted. |
| quality control, pharmaceutical-grade API |
wegovy FDA-supervised cGMP manufacturing; dose accuracy is built into pre-filled pens; batch consistency guaranteed. |
| cost without insurance |
compounded (when legally available) Compounded semaglutide ran $100-300/month vs Wegovy at $1000+/month list - the cost gap drove the entire telehealth-compounding boom of 2023-2024. |
| future supply continuity |
wegovy Novo Nordisk's manufacturing capacity is now sufficient; the shortage that drove compounding is resolved and unlikely to return at scale. |
What the head-to-head data shows
The compounded-vs-branded calculus changed materially in 2024-2025 and the change is permanent for now. The FDA placed semaglutide on its official drug shortage list during 2022-2024, which legally allowed 503A and 503B compounding pharmacies to produce the molecule under FDCA Section 503A/B authority. The FDA officially declared the semaglutide shortage resolved on February 21, 2025, with transition windows: 503A pharmacies could continue compounding until April 22, 2025, and 503B outsourcing facilities until May 22, 2025. After those dates, large-scale compounding of semaglutide outside narrow patient-specific exceptions is no longer permitted under FDA policy. The branded clinical record is the full STEP-1 trial (Wilding et al., NEJM 2021) showing 14.9% body-weight loss at 68 weeks. The compounded version may or may not have used pharmaceutical-grade semaglutide API; quality varied widely by source pharmacy.
Our honest call
If a reader is starting fresh in 2026, branded Wegovy (or Ozempic for diabetes) is the only legally clean answer for semaglutide. The compounded route was a real, legal cost-saving option from 2022 to mid-2025; that window is closed for semaglutide as a default option. If a reader is still running compounded semaglutide in 2026, that needs a hard conversation with the prescribing telehealth provider - the pharmacy may be operating in a narrow patient-specific exception, or it may be operating outside FDA policy. Quality matters either way: any compounded product needs a Certificate of Analysis (third-party purity test) on the batch and a 503B-licensed source. The main compounded vs branded comparison covers the broader category; this page is specifically about semaglutide post-shortage. Read the GLP-1 starter guide before the telehealth call.
Sources and citations
- FDA semaglutide shortage resolution announcement (February 21, 2025)
- FDA Sections 503A and 503B compounding regulations
- Wilding et al., STEP-1 trial, NEJM 2021 (PMID 33567185)
- FDA Wegovy prescribing label (approved Jun 2021)
- FDA warning on compounded GLP-1 risk profile (2024)
Where to go next
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.
Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine. None of this replaces a doctor. Peptides are gray-market in the US for most uses. Talk to a real prescriber before you change anything.